Supplementary Table S2. Baseline, Cell and Treatment Characteristics of Evaluated TIL Patients Treated with or without Ipilimumab before TIL ACT

	All treated TIL patients (N = 57)	Pre IPI OR (N = 13)	No prior IPI NR (N = 44)	p value pre IPI vs. no prior IPI
Baseline Characteristics				
Mean age in years	54	55	52	.092
Female – no. (%)	20 (35%)	6 (46%)	14 (32%)	.509
ECOG performance status – no. (%)				
0	37 (65%)	8 (62%)	29 (66%)	1.0
1	18 (32%)	5 (39%)	13 (30%)	.735
2	2 (4%)	0	2 (5%)	1.0
M stage – no (%)				
M1a	4 (7%)	0	4 (9%)	.564
M1b	8 (14%)	0	8 (62%)	.177
M1c	45 (79%)	13 (100%)	32 (73%)	.05
Lactate dehydrogenase above normal - no. (%)	23 (40%)	4 (31%)	19 (43%)	.218
CNS metastases at baseline – no. (%)	11 (19%)	9 (69%)	2 (5%)	< .001
More than 5 metastasis – no. (%)	45 (79%)	11 (85%)	34 (77%)	.713
HLA-A0201 positive – no. (%)	13 of 56 (23%)	2 (15%)	11 (26%)	.496
TIL and Infusion Product Characteristics - Average				
Days to TIL culture generation	15.9 ± 4.8	14.1 ± 3.2	16.4 ± 5.1	.125
Total cell number in infusion product (x10e9)	51.7 ± 23.7	69.5 ± 23.9	46.5 ± 23.7	.002
CD8 frequency in infusion product (%)	61.8 ± 24.6	70.8 ± 25.8	59.1 ± 23.9	.136
Treatment Characteristics, Grade 3 / 4 Toxicities* and Clinical Outcome				
Days of hospitalization ^ - median (range)	19 (14 - 44)	20 (16 - 36)	19 (14 - 44)	.529
No. of IL-2 doses - average	6.6 ± 3.2	4.1 ± 1.9	7.4 ± 2.9	< .001
Units RBC transfusion - median (range)	4 (0 – 40)	3 (0 – 13)	4 (0 – 40)	.526
Units PLT transfusion - median (range)	18 (0 – 300)	18 (0 – 78)	18 (0 – 40)	.972
Absolute lymphocyte count, 2 weeks after TIL (K/µl) - average	0.90 ± 0.82	0.72 ± 0.71	0.93 ± 0.84	.479
Grade 3 / 4 toxicities – no. (%)				
Pulmonary congestion	27 (47%)	4 (31%)	23 (52%)	.216
Renal failure	11 (19%)	1 (8%)	10 (23%)	.277
Prolonged hypotension	13 (23%)	4 (31%)	9 (21%)	.465
Hyperbilirubinemia	8 (14%)	1 (8%)	7 (16%)	.666
Diarrhea	7 (12%)	0	7 (16%)	.185
Cardiac toxicity	1 (2%)	1 (8%)	0	.228
Confusion	4 (7%)	2 (15%)	4 (6%)	.220
Skin rash	2 (4%)	1 (8%)	1 (2%)	.414
Autoimmunity (vitiligo)	1 (2%)	0	1 (2%)	1.0
Best overall response rate† to TIL (CR + PR)	40%	38%	41%	1.0
Complete response (CR)	5 (9%)	1 (8%)	4 (9%)	1.0
Partial response (PR)	18 (32%)	4 (31%)	14 (32%)	1.0
Non-responders (SD + PD)	34 (60%)	8 (62%)	26 (59%)	1.0
Median overall survival (from TIL infusion to DOD in months)	15.2	13.4	16.5	.590

Supplementary Table S2. Baseline, Cell and Treatment Characteristics of Evaluated TIL Patients Treated with or without Ipilimumab before TIL ACT

[&] Percent CD8 cytotoxic T cells, all other cells are CD4 T helper cells. *Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0. One unevaluated patient died of cardiac arrest before cell infusion [†] According to RECIST v1.1 guidelines. ^ Days of hospitalization include 7 days of non myeloablative preconditioning. Abbreviations: IPI, ipilimumab; ECOG, Eastern Cooperative Oncology Group; M stage, metastasis stage; CNS, central nervous system; HLA, human leukocyte antigen; REP, rapid expansion procedure; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; IL-2, interleukin-2; RBC, red blood cells; PLT, platelets; TIL, tumor infiltrating lymphocyte; DOD, died of disease